Table 1.

c-Fos expression in mice after limited access to test solutions

B6 StrainD2 StrainANOVA
WaterSucroseEthanol/sucroseWaterSucroseEthanol/sucrose
Hippocampus
 DG5.0  ± 1.16.1  ± 1.04.5  ± 0.88  ± 1.312.5  ± 7.26.2  ± 0.9
 CA10.3  ± 0.11.1  ± 0.60.2  ± 0.10.3  ± 0.20.3  ± 0.20.3  ± 0.2
 CA20  ± 00  ± 00.1  ± 0.10  ± 00.4  ± 0.20.4  ± 0.4
 CA32.0  ± 0.71.5  ± 0.42.2  ± 1.01.3  ± 0.71-a3.7  ± 0.81.1  ± 0.41-aGxS
Septum and striatum
 AcbC0.1  ± 0.10.3  ± 0.20.1  ± 0.10.1  ± 0.10.4  ± 0.20.4  ± 0.2
 AcbS0.9  ± 0.41.5  ± 0.31.3  ± 0.31.6  ± 0.21.9  ± 0.41.6  ± 0.3
 BNST2.8  ± 0.53.4  ± 0.92.8  ± 0.63.3  ± 0.83.3  ± 0.92.0  ± 0.8
 LSd2.0  ± 0.32.6  ± 0.51.4  ± 0.61.0  ± 0.32.7  ± 0.51.6  ± 0.4G
 LSi1.9  ± 0.52.3  ± 0.31.0  ± 0.21-a0.9  ± 0.42.2  ± 0.41-b2.0  ± 0.31-bG, GxS
 LSv1.4  ± 0.21.7  ± 0.50.8  ± 0.31.3  ± 0.51.4  ± 0.41.5  ± 0.5
 MS1.6  ± 0.42.0  ± 0.51.4  ± 0.41.3  ± 0.31.2  ± 0.40.5  ± 0.2S
Amygdala
 La0  ± 00.1  ± 0.10.1  ± 0.10  ± 00  ± 00.4  ± 0.1
 BLA1.0  ± 0.51.8  ± 0.51.7  ± 0.70.4  ± 0.21.6  ± 0.70.9  ± 0.4
 CeM1.3  ± 0.61.1  ± 0.51.7  ± 0.71.7  ± 0.52.6  ± 0.62.7  ± 0.8
 CeL0.7  ± 0.41.6  ± 0.62.0  ± 0.60.9  ± 0.51.2  ± 0.61.7  ± 0.7
Hypothalamus and thalamus
 AHP6.8  ± 1.45.7  ± 1.45.8  ± 1.62.8  ± 1.77.3  ± 3.81.1  ± 0.5
 LH1.8  ± 0.81.3  ± 0.50.6  ± 0.30.9  ± 0.32.9  ± 0.81.1  ± 0.8
 Pa9.0  ± 4.34.8  ± 1.49.0  ± 2.82.8  ± 1.22.1  ± 0.63.7  ± 3.0S
 PV13.7  ± 5.17.0  ± 1.212.0  ± 3.520.1  ± 5.335.7  ± 6.722.9  ± 5.8S1-160
 SO1.6  ± 0.40.9  ± 0.30.9  ± 0.31.7  ± 0.21.0  ± 0.41.7  ± 0.6
Neocortex
 M0.4  ± 0.30.4  ± 0.20.2  ± 0.10.3  ± 0.20.1  ± 0.10.2  ± 0.2
 Pir3.9  ± 0.65.3  ± 0.75.1  ± 1.35.4  ± 1.06.7  ± 1.23.7  ± 0.7
 RS0.3  ± 0.20.2  ± 0.10  ± 00.1  ± 0.10.6  ± 0.21.5  ± 1.1
 S10.3  ± 0.20.3  ± 0.20.3  ± 0.20.3  ± 0.20.4  ± 0.20.3  ± 0.2
Midbrain
 EW6.8  ± 1.210.4  ± 1.717.9  ± 1.93.7  ± 1.04.8  ± 0.87.4  ± 3.2G1-160, S1-160
 VTA0.6  ± 0.20.4  ± 0.20.4  ± 0.20.6  ± 0.30.2  ± 0.10.3  ± 0.2

  • Data are presented as mean ± SEM. AcbC, Core of nucleus accumbens (+1.1 mm); AcbS, shell of nucleus accumbens (+1.1 mm); AHP, posterior portion of anterior hypothalamus (−1.22 mm); BLA, basolateral amygdala (−1.2 mm); BNST, bed nucleus of stria terminalis (+0.5 mm); CA1 (−1.5 mm); CA2 (−1.5 mm); CA3 (−1.5 mm); CeL and CeM, capsular, lateral, and medial divisions of central nucleus of amygdala (−1.2 mm); DG, dentate gyrus (−1.5 mm); EW, Edinger-Westphal nucleus (−3.8 mm); LH, lateral hypothalamus (−0.9 mm); LSD, LSI, and LSV, lateral septum dorsal, intermediate, and ventral (+0.7 mm); M, motor cortex (−1.2 mm); MS, medial septum (+0.7 mm); Pa, paraventricular nucleus of hypothalamus (−0.9 mm); PH, posterior hypothalamus (−2.5 mm); Pir, piriform cortex (−1.2 mm); PV, paraventricular nucleus of thalamus (−0.9 mm); RS, retrosplenial agranular cortex (−1.2 mm); S1, somatosensory cortex (−1.2 mm); VTA, ventral tegmental area (−3.5 mm); ANOVA: G, significant effect of group; S, significant effect of strain; GxS, significant group by strain interaction, p< 0.05.

  • ↵F1-160 p < 0.001.

  • ↵F1-a Fisher's post hoccomparisons for brain areas with significant interactions. Significantly different from sucrose group of same strain.

  • ↵F1-b Fisher's post hoccomparisons for brain areas with significant interactions. Significantly different from water group of same strain.